Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A. Cremolini C, et al. Among authors: mezi s. Lancet Oncol. 2015 Oct;16(13):1306-15. doi: 10.1016/S1470-2045(15)00122-9. Epub 2015 Aug 31. Lancet Oncol. 2015. PMID: 26338525 Clinical Trial.
Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era.
Botticelli A, Pomati G, Cirillo A, Mammone G, Ciurluini F, Cerbelli B, Sciattella P, Ralli M, Romeo U, De Felice F, Catalano C, Vullo F, Della Monaca M, Amirhassankhani S, Tomao S, Valentini V, De Vincentiis M, Tombolini V, Della Rocca C, Polimeni A, di Gioia C, Corsi A, D'Amati G, Mezi S, Marchetti P. Botticelli A, et al. Among authors: mezi s. J Transl Med. 2021 Jul 12;19(1):303. doi: 10.1186/s12967-021-02975-3. J Transl Med. 2021. PMID: 34253248 Free PMC article.
A network approach to define the predictive role of immune profile on tumor response and toxicity of anti PD-1 single agent immunotherapy in patients with solid tumors.
Mezi S, Pomati G, Fiscon G, Amirhassankhani S, Zizzari IG, Napoletano C, Rughetti A, Rossi E, Schinzari G, Tortora G, Lanzetta G, D'Amati G, Nuti M, Santini D, Botticelli A. Mezi S, et al. Front Immunol. 2023 Jul 7;14:1199089. doi: 10.3389/fimmu.2023.1199089. eCollection 2023. Front Immunol. 2023. PMID: 37483633 Free PMC article.
The 5-Ws of immunotherapy in head and neck cancer.
Botticelli A, Mezi S, Pomati G, Cerbelli B, Di Rocco C, Amirhassankhani S, Sirgiovanni G, Occhipinti M, Napoli V, Emiliani A, Mazzuca F, Tomao S, Nuti M, Marchetti P. Botticelli A, et al. Among authors: mezi s. Crit Rev Oncol Hematol. 2020 Sep;153:103041. doi: 10.1016/j.critrevonc.2020.103041. Epub 2020 Jun 30. Crit Rev Oncol Hematol. 2020. PMID: 32629362 Review.
The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy.
Botticelli A, Pomati G, Cirillo A, Scagnoli S, Pisegna S, Chiavassa A, Rossi E, Schinzari G, Tortora G, Di Pietro FR, Cerbelli B, Di Filippo A, Amirhassankhani S, Scala A, Zizzari IG, Cortesi E, Tomao S, Nuti M, Mezi S, Marchetti P. Botticelli A, et al. Among authors: mezi s. Front Immunol. 2022 Nov 3;13:974087. doi: 10.3389/fimmu.2022.974087. eCollection 2022. Front Immunol. 2022. PMID: 36405727 Free PMC article.
67 results